TLSI TriSalus Life Sciences, Inc.
Mergers ·
TriSalus agreed to sell 5,500,000 shares at $4.00 in a private placement of about $22.0 million. The same deal ties it to an exchange offer for its Series A preferred stock, and the filing says the preferred terms would change.
TriSalus says it cannot file its 2024 annual report on time after finding errors in stock-based compensation and clinical trial expenses. It expects to file by the fifteenth calendar day after the due date. Preliminary 2024 revenue was $29.4 million.
The company found errors in the timing of stock-based compensation and clinical trial expenses. It expects to file its annual report within fifteen calendar days of the due date.
The Second Tranche loan matures on April 30, 2029. Warrants issued to the initial lender and its affiliate carry an exercise price of $5.4787 and a term of 7 years.
TriSalus Life Sciences is an oncology focused medical technology business that aims to improve outcomes for patients with solid tumors by combining its delivery technology with standard-of-care therapies and with its investigational immunotherapy, nelitolimod. Its Pressure-Enabled Drug Delivery (PEDD) method modulates pressure and flow within blood vessels to improve intravascular drug delivery into tumors. The on-market TriNav Infusion System, a 510(k) cleared device using PEDD, is used mainly for transarterial radioembolization and chemoembolization in primary liver cancer and liver metastases. TriSalus is also generating clinical data in thyroid, uterine artery and genicular artery embolization. Its Pancreatic Retrograde Venous Infusion device is also 510(k) cleared and is designed for pancreatic tumors, but it has not yet been commercialized. Nelitolimod, a class C Toll-like receptor 9 agonist, is being studied to reprogram immune cells in the liver and pancreas, and the company has completed Phase I and Phase Ib trials. It may seek a partner to advance nelitolimod into Phase II trials.
| Product or program | What it is | Stage |
|---|---|---|
| TriNav Infusion System | Interventional radiology device using PEDD technology for liver tumor procedures | on-market, 510(k) cleared |
| Pancreatic Retrograde Venous Infusion (PRVI) device | Device for infusions into pancreatic tumors through the venous vasculature | 510(k) cleared, not yet commercialized |
| Nelitolimod | Investigational class C Toll-like receptor 9 agonist for liver and pancreas tumors | Phase I and Phase Ib completed |
| PEDD technology | Pressure-Enabled Drug Delivery method for intravascular delivery into solid tumors |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $45.2 million | $29.4 million |
| Research and development | $15.0 million | $17.7 million |
| Net income (loss) | -$39.2 million | -$30.0 million |
| Cash from operations | -$18.0 million | -$40.8 million |
| Cash and equivalents | $20.4 million | $8.5 million |
Our latest story on this, dated Apr 30, 2025: "TriSalus agrees to sell 5,500,000 shares at $4.00 in $22.0 million private placement". The story links the filing or release it is based on. Read the story.
TriSalus Life Sciences, Inc. trades under the ticker TLSI on NASDAQ.
TriSalus Life Sciences, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for TriSalus Life Sciences, Inc. is 1826667. Its filings are on SEC EDGAR.
61,574,600 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06.
Our directory records TriSalus Life Sciences, Inc. under United States.
Our directory classifies TriSalus Life Sciences, Inc. as: Drug / device combination. This is a directory classification, not a description of the pipeline.
The ISIN recorded for TriSalus Life Sciences, Inc. is US89680M1018.
aibio.space lists TriSalus Life Sciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
TriSalus Life Sciences is an oncology focused medical technology business that aims to improve outcomes for patients with solid tumors by combining its delivery technology with standard-of-care therapies and with its investigational immunotherapy, nelitolimod. Its Pressure-Enabled Drug Delivery (PEDD) method modulates pressure and flow within blood vessels to improve intravascular drug delivery into tumors.
TriNav Infusion System: Interventional radiology device using PEDD technology for liver tumor procedures Stage: on-market, 510(k) cleared.
Pancreatic Retrograde Venous Infusion (PRVI) device: Device for infusions into pancreatic tumors through the venous vasculature Stage: 510(k) cleared, not yet commercialized.
$45.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
TriSalus Life Sciences, Inc. reported a net loss of $39.2 million for the fiscal year ended Dec 31, 2025, and used $18.0 million of cash in operations, per its annual report to the SEC.
Reported a financing. SEC Form 424B5. Source
Offered to buy back its own securities. SEC Form SC TO-I. Source
Filed documents for a merger or acquisition. SEC Form 425. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 2.03,3.02). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio